GlassScriptPhysician profile
Peter D Kuhlman
NPI 1891789228
$1,255.24
in general payments reported to CMS, 2019-2025
10 companies · $158 in 2025
The $158 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $743 · 2020: $124 · 2021: $215 · 2022: $13.89 · 2025: $158.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $158.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $158.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $706.90 | 2019-2025 | |
| Amgen INC. | $129.22 | 2019-2025 | Repatha |
| Esperion Therapeutics, INC. | $124.38 | 2020 | |
| Shockwave Medical, INC | $112.04 | 2021 | |
| Abbott Laboratories | $60.60 | 2019 | |
| Gilead Sciences, INC. | $48.92 | 2019 | |
| Janssen Pharmaceuticals, INC | $26.04 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $21.28 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $13.89 | 2022 | |
| Boston Scientific Corporation | $11.97 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Kuhlman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.